MCM
NWBO

MAI Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

MAI Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$6.4K – 3514
2024
Q3 		$6.4K Hold
20,000
– – ﹤0.01% 1079
2024
Q2 		$8.54K Hold
20,000
– – ﹤0.01% 1228
2024
Q1 		$10.4K Hold
20,000
– – ﹤0.01% 1203
2023
Q4 		$14K Hold
20,000
– – ﹤0.01% 1090
2023
Q3 		$18.2K Hold
20,000
– – ﹤0.01% 1031
2023
Q2 		$11.4K Hold
20,000
– – ﹤0.01% 1036
2023
Q1 		$12.5K Hold
20,000
– – ﹤0.01% 1023
2022
Q4 		$15.7K Buy
+20,000
New +$15.7K ﹤0.01% 987

Other funds holding NWBO

MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.19B AUM 34.45% 1-Year Est. Return

MAI Capital Management's NWBO Position: Q4 2024 in Review

MAI Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2024, closing a stake of 20,000 shares — an estimated $6.4K sold.

MAI Capital Management first reported a position in NWBO in Q4 2022 and held it in 8 quarters. The position peaked at $18.2K in Q3 2023. 11 funds tracked by Wall St. Rank hold NWBO as of Q4 2024.

  • MAI Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2024 after selling out during the quarter.
  • MAI Capital Management sold 20,000 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2024, an estimated $6.4K.
  • MAI Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2022 and held it in 8 quarters.
  • MAI Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $18.2K in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2024.

Based on MAI Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.